According to the latest preliminary statistics from China's National Medical Products Administration (NMPA), the total value of outbound licensing deals for innovative Chinese drugs exceeded $60 billion during the first three months of 2026. @MedIPXcom@tymedorg@APEC2026@hkumed
As of February 15, there have been 39 license-out transactions for innovative drugs in China, with initial payments of approximately US$2.953 billion and a total amount exceeding US$49 billion.
@tymedorg@MedIPXcom
HKSAR Government's Commerce and Economic Development Bureau, the IP Department, and the HKMA jointly launched the IP Financing Sandbox, marking a significant milestone for Hong Kong in promoting IP financing, further developing the IP trading ecosystem, and fostering innovation.